Non-invasive Brain Tumor Molecular Diagnostics and Monitoring
Brain Tumor
What this study involves
The registry says this study is recruiting. Individual locations may have different availability.
- Study type
- Observational
- Phase
- Not applicable / not listed
- Age range
- 18 years - 99 years
- Sex eligible
- All sexes
- Healthy volunteers
- Accepted
- Participants
- 200 Estimated
These are starting points, not an eligibility decision. The research team must review the full requirements.
About the research
This prospective multicenter study aims to enroll GBM patients who will undergo repeated assessments (preoperatively and 3 months post-surgery) to detect circulating tumor cells and analyze the transcriptomic profiles of EVs in their blood. The prognostic and monitoring significance of these biomarkers to disease course (assessing treatment efficacy, resistance incidence, tumor progression) will be evaluated.
Concurrently, proteomic profiles typical of GBM will be analyzed in blood and ocular secretion samples from GBM patients, patients with low-grade gliomas, and patients without brain tumors to identify and validate novel protein biomarkers suitable for disease monitoring. Additionally, this study proposes an innovative approach to monitor GBM patients by investigating the presence of GBM-specific nucleic acid fragments in urine.
Who may be able to participate?
The list below is the sponsor’s full registry wording. It can include conditions, prior treatment, test results and other requirements. A match in search does not mean you qualify.
Inclusion Criteria: Adult patients with brain tumors -
Exclusion Criteria: No other cancer; no inflammatory disease
\-
Study population
Inhabitants of Olomouc region
Understand screeningTreatment, groups and participation
The registry may describe treatments and study duration without a complete visit calendar. Ask the study team for the exact schedule, procedures, risks, costs and alternatives. Keep your usual care plan unless your treating clinician tells you otherwise.
- Assignment
- Not reported
- Masking
- Not reported
Glioblastoma multiforme
Patients with GBM
Diagnostic Test: Diagnostic test
Low-grade glioma
Patients with low-grade gliomas.
Diagnostic Test: Diagnostic test
Control group
Patients without cancer or systemic inflammation
Diagnostic Test: Diagnostic test
Diagnostic test DIAGNOSTIC_TEST
No intervention among the arms. The diagnostic, prognostic, predictive and follow-up value of tested biomolecules will be analyzed.
What researchers are measuring
Outcome measures describe what is being studied. They are not proof that a treatment works.
Primary measures
Proteomic profiles of proximal liquids in brain tumor patients
Time frame: 2020-2023
The protein profiles will be measured in ocular secretion and plasma samples of patients wiht GBM, low-grade glioma and control cohort. Candidate proteins will be correleted with clinical parameters. The number of patients with identified prognostic biomarkers will be reported.
Circulating tumor cells (CTCs) for non-invasive monitoring of GBM patients.
Time frame: 2020-2030
The number of CTCs and their molecular characteristics will be measured in peripheral blod of GBM patients. The CTCs counts will be correleted with the clinical parameters. The number of patients with the presence or absence of CTCs will be reported.
Extracellular vesicles (EVs) for non-invasive monitoring of GBM patients.
Time frame: 2020-2030
The RNA profiles of EVs will be measured in plasma samples of patients wiht GBM. Candidate RNAs will be correleted with clinical parameters. The number of patients with identified prognostic RNAs will be reported.
Urine as a source of GBM-specific nucleic acids fragments for disease monitoring.
Time frame: 2025-2030
The GBM-specific nucleic acids fragments will be measured in urine of GBM patients. Candidate nucleic acids will be correleted with clinical parameters. The number of patients with identified prognostic biomolecules will be reported.
Review the complete result tables and limitations in the official record.
Open official results ↗Research locations (1)
The overall study status and a local site’s status can differ. Confirm that location’s availability before traveling.
1 locations
Department of Neurosurgery, University Hospital OlomoucOlomouc, CzechiaRecruiting
Study team and timeline
- Lead sponsor
- The Institute of Molecular and Translational Medicine, Czech Republic
- Study start
- Jan 1, 2020 Actual
- Primary completion
- Dec 31, 2028 Estimated
- Study completion
- Dec 31, 2030 Estimated
- First posted
- Jul 15, 2024 Actual
- Last updated
- Nov 10, 2026 Actual
Official study contacts
Official study title
Non-invasive Brain Tumor Diagnosis Through Analysis of Proximal Fluids, Circulating Tumor Cells, and Biomolecules
Ask Wellness Clinical Research
Your message goes to WCR, including when this study is run by another organization. WCR may offer general guidance but may not operate this trial, have access to its team or be able to enroll you.
Source: ClinicalTrials.gov API v2. Information is submitted by sponsors and investigators. NLM does not approve the safety or science of all listed studies. Registry disclaimer.
Retrieved: Nov 12, 2026 · Last registry update: Nov 10, 2026